Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.66 |
| ▸ | RAF1 | P04049 | 7/20 | 0.65 |
| ▸ | ULK1 | O75385 | 1/20 | 0.65 |
| ▸ | KIF15 | Q9NS87 | 1/20 | 0.65 |
| ▸ | TGM2 | P21980 | 5/20 | 0.55 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.54 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394541 | 1.00 | JAK3 (0.66) | JAK3RAF1ULK1KIF15TGM2 | |
| SCHEMBL5774559 | 0.88 | RAF1 (0.77) | JAK3RAF1ULK1KIF15TGM2 | |
| SCHEMBL5774564 | 0.88 | RAF1 (0.77) | JAK3RAF1ULK1KIF15TGM2 | |
| SCHEMBL5084106 | 0.88 | RAF1 (0.67) | JAK3RAF1ULK1KIF15TLK2 | |
| SCHEMBL1394705 | 0.88 | RAF1 (0.67) | JAK3RAF1ULK1KIF15TLK2 | |
| SCHEMBL5080462 | 0.87 | RAF1 (0.76) | JAK3RAF1ULK1KIF15TLK2 | |
| SCHEMBL1395408 | 0.87 | RAF1 (0.76) | JAK3RAF1ULK1KIF15TLK2 | |
| SCHEMBL7982366 | 0.81 | RAF1 (0.69) | JAK3RAF1ULK1KIF15TLK2 | |
| SCHEMBL1394485 | 0.80 | RAF1 (0.61) | JAK3RAF1KIF15TGM2PIK3C3 | |
| SCHEMBL1394486 | 0.80 | RAF1 (0.61) | JAK3RAF1KIF15TGM2PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010048273-A2 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-1003721-B1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LTD (GB) | 2006-11-02 | — | — | EP | disclosed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, NEFM | JAK3 3745/4885RAF1 3380/4885ULK1 1552/4885 |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, CLN6, SNCA | JAK3 4452/4885RAF1 4033/4885ULK1 1148/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | JAK3 3472/4885RAF1 4132/4885ULK1 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.